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Abstract 
BACKGROUND: Cell therapies offer a promising potential in promoting bone regeneration. Stem cell therapy 
presents attractive care modality in treating degenerative conditions or tissue injuries. The rationale behind this is 
both the expansion potential of stem cells into a large cell population size and its differentiation abilities into a 
wide variety of tissue types, when given the proper stimuli. A progenitor stem cell is a promising source of cell 
therapy in regenerative medicine and bone tissue engineering. 
AIM: This study aimed to compare the osteogenic differentiation and regenerative potentials of human 
mesenchymal stem cells derived from human bone marrow (hBM-MSCs) or amniotic fluid (hAF-MSCs), both in 
vitro and in vivo studies. 
SUBJECTS AND METHODS: Human MSCs, used in this study, were successfully isolated from two human 
sources; the bone marrow (BM) and amniotic fluid (AF) collected at the gestational ages of second or third 
trimesters. 
RESULTS: The stem cells derived from amniotic fluid seemed to be the most promising type of progenitor cells 
for clinical applications. In a pre-clinical experiment, attempting to explore the therapeutic application of MSCs in 
bone regeneration, Rat lumbar spines defects were surgically created and treated with undifferentiated and 
osteogenically differentiated MSCs, derived from BM and second trimester AF. Cells were loaded on gel-foam 
scaffolds, inserted and fixed in the area of the surgical defect. X-Ray radiography follows up, and 
histopathological analysis was done three-four months post- operation. The transplantation of AF-MSCs or BM-
MSCs into induced bony defects showed promising results. The AF-MSCs are offering a better healing effect 
increasing the likelihood of achieving successful spinal fusion. Some bone changes were observed in rats 
transplanted with osteoblasts differentiated cells but not in rats transplanted with undifferentiated MSCs. Longer 
observational periods are required to evaluate a true bone formation. The findings of this study suggested that the 
different sources; hBM-MSCs or hAF-MSCs exhibited remarkably different signature regarding the cell 
morphology, proliferation capacity and osteogenic differentiation potential  
CONCLUSIONS: AF-MSCs have a better performance in vivo bone healing than that of BM-MSCs. Hence, AF 
derived MSCs is highly recommended as an alternative source to BM-MSCs in bone regeneration and spine 
fusion surgeries. Moreover, the usage of gel-foam as a scaffold proved as an efficient cell carrier that showed bio-
compatibility with cells, bio-degradability and osteoinductivity in vivo. 
 
 
 
 
 
Introduction 
 
Mesenchymal stem cells (MSCs) are 
multipotent stem cells that can self-renew and 
differentiate into different cell types including 
osteoblasts, chondrocytes, tenocytes, adipocytes, and 
hepatocytes which make them a promising tool in 
tissue engineering and regenerative medicine 
applications. MSCs can be derived from different 
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human sources including; bone marrow tissue, fetal 
amniotic fluid, adipose tissue cord blood, umbilical 
cord, placenta and dental pulp [1], [2], [3]. 
MSC originating from the stroma of the bone 
marrow (BM) was one of the first known MSC, and are 
also more advanced in clinical trials. BM-MSCs 
generally serve as the “gold standard” against which 
other MSC sources are compared. It is well known 
that bone marrow stroma contains progenitor cells 
with osteogenic potential, generally referred to as 
mesenchymal stem cells or bone marrow stromal cells 
(BM-MSCs) [4]. Human BM-MSCs have been 
demonstrated to differentiate toward the osteoblastic 
lineage in-vitro and to form bone tissue upon ectopic 
implantation [5]. 
Bone marrow-derived mesenchymal stem 
cells (BM-MSCs) have shown a great promise in 
animal studies and even in a few clinical trials for 
skeletal tissues regeneration [6]. Harvesting BM-
MSCs from a patient is an invasive and rather painful 
procedure. Furthermore, the number, proliferative 
capacity, and differentiation potential of BM-MSCs 
decline with age suggesting that tissue-engineering 
strategies based on these cells might not be feasible 
in older patients [7]. 
Fetal Amniotic Fluid Stem cells (AF-MSCs) 
seems a very promising type of cells and its 
application is rapidly growing in regenerative 
research. Almost ten years ago, the first suggestion of 
human amniotic fluid as a new putative source for 
stem cells was reported [8]. The first evidence for the 
existence of AF-MSCs was demonstrated by the 
discovery of a highly proliferative cell type in human 
amniotic fluid expressing the pluripotent stem cell 
marker Oct4 [9]. AF-MSCs have been applied to 
critically sized femoral bone defects of a nude rat in 
combination with biomaterial scaffold and shown the 
bone formation in rat femoral defect [10]. 
AF-MSCs cells demonstrated high potential in 
differentiation into hematopoietic [11], neurogenic [9],  
[12], [13], [14], osteogenic [13], [14], chondrogenic 
[14], adipogenic [13], [14], renal [15], hepatic [16], and 
various other lineages [9], [13]. The biological 
properties and markers expression pattern of AF-
MSCs appears to be more similar to that of embryonic 
stem (ES) cells [17]. They express many but not all of 
the markers of embryonic stem cells (ESCs) [18]. 
However, they require no feeder layers for culture, 
they have not been observed to form teratomas in-
vivo and are capable of > 300 population doublings in 
culture [19]. It is also possible to generate monoclonal 
genomically stable AF-MSC lines, harbouring high 
proliferative potential without raising ethical issues 
[20]. 
Both BM- and AF-derived MSCs offer a very 
promising and much more abundant potential cell-
source for repair of bone defects, particularly the 
vertebral spines defects. The vertebral spine (or 
backbone) plays an important role in the stability of 
the upper body and the protection of the Spinal Cord 
[21]. Vertebral spines underwent pathological 
degeneration, or developed cancerous tumours or 
exposed to accidents are treated by surgical 
intervention, which employs autologous bone graft 
transplantation or substitutes for non-union defects 
and replacement of damaged tissue [22], [23]. 
However, several inconveniences are likely to occur 
with surgical interventions. It includes extra surgery to 
remove grafted bone from the patient's body, 
increased potential operations’ complications [23]. 
Additionally, the amount of bone available for grafting 
might be insufficient. Moreover, the cost is very high 
[24]. 
In this study, we have isolated human MSCs 
(hMSCs) from two sources; bone marrow and 
amniotic fluid to compare the proliferation and 
osteogenic differentiation potentials in-vitro and 
evaluate the ability of transplanted human fetal 
amniotic fluid and adult bone marrow stem cells in the 
enhancement of functional repair in "rats" with 
induced spine defect.  
 
 
Subjects and Methods 
 
The Ethics Committee of the National 
Research Center, Cairo, Egypt, approved the study 
protocol and all participants gave informed consent. 
Mesenchymal stem cells were isolated from 
two different human sources; Bone Marrow and 
Amniotic fluid. Bone marrow (BM) samples were 
aspirated from the sternum of healthy human 
subjects, following their consent, at Cairo-Nasser 
Institute. BM aspiration was done as a clinical care 
procedure in the process of doing the cross-
matching procedure for donor BM transplantation. The 
subjects age range was between 6-33 years old (n = 
6). The third-trimester AF samples were collected 
during two deliveries of the elective cesarean section. 
Eight women ‟ AF samples were collected, whereas 
seven samples only (n = 7) were successfully isolated. 
The maternal age range was from 21 to 38 years. 
Second trimester AF samples (collected between the 
14th and 18th weeks of gestation) were obtained by 
amniocentesis from five women, three (n = 3) were 
successfully isolated. The age range was between 21 
to 38 years old. 
Bone marrow cells were isolated by ficoll 
gradient separation of mononuclear cells [25]. Second 
and third-trimester amniotic fluid cells were isolated by 
centrifugation and pelleting of cells [19]. We didn’t 
study the effect of the parameters; sex and age on the 
MSCs isolation protocol, since isolation of AF only 
from pregnant female but BM isolation could be from 
both sex. 
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Isolation of human Bone Marrow-derived 
Mesenchymal Stem Cells was done by RosetteSep® 
Human Mesenchymal Stem Cell Enrichment Cocktail 
(RosetteSep, Stem Cell Technologies, Canada) was 
applied to the bone marrow to get rid of the unwanted 
cells by negative selection. Bone marrow 
mononuclear cells were isolated from the bone 
marrow sample by Ficoll-Paque™ PLUS density 
gradient solution (Stem Cell Technologies, GE 
Healthcare, Canada). Mononuclear cells were plated 
at a density of 10,000 cells/cm
2
 in 60 mm plastic 
tissue culture dishes in complete culture media 
containing Alpha-MEM (Lonza, Belgium), 10% FBS 
(Lonza, Belgium), 1% glutamax (Gibco, Invitrogen, 
Life Technologies, USA), 1% 10,000 U/ml penicillin 
and 10,000 U/ml streptomycin (Pen-Strep, Lonza, 
Belgium), (3 ng/ml) fibroblast growth factor basic 
(Sigma-Aldrich, USA) and incubated in a humid 5% 
CO2 atmosphere at 37ºC in a CO2 incubator. 
Mesenchymal stem cells adhered to the culture plates, 
meanwhile the other non-adherent cells were 
discarded upon the first replaced media. Media was 
replaced twice a week. 
Isolation of amniotic fluid-derived 
Mesenchymal Stem Cells was done by centrifugation 
and pelleting of cells [19]. Cells were cultured in α-
MEM media (Lonza) containing 20% FBS (Lonza), 
glutamax (Invitrogen), penicillin-streptomycin (Lonza) 
and bFGF (Sigma). Media was exchanged two times 
/week and passage was done when the cells reached 
the confluence of about 75%. 
Culture Expansions were maintained to reach 
about 80% confluence, and then cells were passage 
and reseed. Manual scraping technique using cell 
scraper (Corning incorporated, Costar, Mexico) and 
collection of the cells, followed by centrifugation and 
re-suspension in the complete medium then re-
seeding of cells in culture plates. 
Differentiation of MSCs into bone-forming 
cells was initiated at third passage. Cells at 70% 
confluence were used for osteogenic differentiation, 
cultured in DMEM containing 20% FBS, 100 µg/ml 
penicillin & streptomycin and 1% glutamax, L-ascorbic 
acid 2-phosphate, β-glycerol phosphate and 
dexamethasone [26]. A comparable control culture 
maintained in proliferation media was generated for 
each sample. Two similar simultaneous sets were 
created at the same time; first set: plates in 
differentiation media, as well as plates in proliferation 
media, were kept in the corresponding culture media 
for 14 days before being passed for characterisation 
protocols. The second set: plates in differentiation 
media and plates in proliferation media were kept in 
its culture media for 29 days before characterisation. 
Characterisation of osteogenic differentiation 
was done using Alizarin Red staining. Alizarin red S 
(Sigma) staining for the detection of mineralized 
nodules in the differentiated cultures was done 
according to the manufacturer’s instructions. 
Cultures maintained in osteogenic and control 
media for 14 days were used for early alizarin 
staining, whereas the second similar set remained in 
its corresponding media for 29 days were used for late 
alizarin staining. 
Alizarin Red staining, Monolayers in the 
plates were washed three times with PBS and fixed in 
70% ethanol at room temperature for one hour. 
Monolayers were then washed three times with dH2O 
before the addition of 1.3 g% Alizarin Red S (Sigma) 
(pH 4.2). The plates were incubated at 37ºC for one 
hour with gentle shaking. After aspiration of the 
unincorporated dye, the plates were washed with 
dH2O till colour disappears. The plates were then 
washed with PBS for 5 min. Distal H2O was added to 
the plate to prevent cell dryness, and the plates 
became ready for visual inspection using an inverted 
microscope where calcium deposits were stained 
orange-red. 
The in vivo study was performed by 
transplantation of human stem cells (MSC at passage 
3 and differentiated osteogenic cells after 29 days of 
osteogenic induction) into rat spines. Six male 
Sprague Dawley rats weighed 200-300 gm were 
divided into two groups; each group consists of three 
rats. 
All animals experiments were conducted after 
animal ethics approvals with approval numbers 
16/263, and all animals were treated humanely. 
BM Group: this group is being transplanted 
with BM-derived stem cells. Transplantation of BM-
MSCs was done in duplicate: Two rats labeled as 
Osteogenic 1 and Osteogenic 2 had received MSCs 
differentiated into osteogenic progenitors 
(experimental group). Cells used for implantation 
underwent osteogenic induction for 29 days. A third 
rat (control one), had received matched but 
undifferentiated BM-derived MSCs.  
AF Group: this group is transplanted with 
second-trimester AF-derived stem cells. Two rats; 
Osteogenic 1 and Osteogenic 2 had received MSCs 
differentiated into osteogenic progenitor cells. 
Transplanted cells were derived from second-
trimester pregnancy and completed 30 days in 
osteogenic induction media. The third rat (control 
one), had received AF-undifferentiated MSCs. 
An absorbable gelatin sponge, gel foam 
(Cutanplast®, Italy), was used as a scaffold to load 
the cells on. 
The rats were anesthetized by being injected 
intraperitoneally with 200 µl (10 mg) freshly prepared 
Thiopental Sodium and 200 µl (0.093 mg) Xyla-Ject® 
(23.3 mg/ml Xylazine Hydrochloride). 
Induction of rat spine bone defects in both AF-
MSCs and BM-MSCs groups: Spines “decortication” 
defects have been created in the transverse 
processes of spines at the lumbar region, consists of 
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5 vertebrae that have a larger bed to work on. 
Scaffold Implantation loaded with 
approximately 2 million cells, Cell-loaded gel foams, 
were applied and fitted in the decorticated areas of the 
lumbar spines in the backbone of the rats. 
The X-ray photographing of the rat’s 
backbone was done for both groups at different time 
intervals to follow up the healing process in the 
osteogenic versus control rats. 
In the BM transplanted group: X-ray filming 
was done after 4, 9, 13 and 17 weeks from the first 
day of cells transplantation. For the AF transplanted 
group: X-ray filming was done after 4, 8 and 12 weeks 
(as this AF group had started later than the BM 
group). 
Histological analysis was performed for 
qualitative evaluation of new bone formation in the 
defected lumber spine. Three-four months post-
implantation rats were sacrificed according to the 
recommendation of the ethical committee of the 
National Research Centre for Animal Experiment. The 
specimens of rat defected lumber spines were cut in 
blocks 0.5-1 cm apart from the defect, decalcified in 
4% formic acid at room temperature and routinely 
prepared to be embedded in paraffin blocks. 
Lateromedial 5 µm thick sections were obtained and 
stained with hematoxylin and eosin to be examined by 
a light microscope [26]. 
 
 
Results 
 
Proliferative potential and morphological 
criteria of BM-MSCs and AF-MSCs, human 
Mesenchymal Stem Cells (hMSCs) were compared. 
The primary BM-MSCs and AF-MSCs cultured cells 
took a similar period (10-14 days) to reach confluence 
and showed comparable plating efficiency (Figure 1A 
and 1E), respectively. The BM-MSCs showed a higher 
proliferation rate than the second-trimester AF-MSCs 
at the first Passage (Figure 1B) and (Figure 1F) 
respectively. After subsequent passages (the 2
nd
 and 
3
rd
 passages), both BM-MSCs and AF-MSCs showed 
spindle-shaped fibroblast morphology (Figure 1C and 
1G) (Figure 1D and 1H), respectively. The 
proliferation capacity of BM samples differed from one 
sample to another, but generally, the younger age 
derived sample showed a higher proliferation rate and 
more typical spindle cell morphology than the older 
age sample (data not shown). 
Proliferative potential and morphological 
criteria of 2
nd
 and 3
rd
 trimester AF: The cells can form 
colonies (clonogenic ability) at the primary culture that 
appeared mostly in the 2
nd
 trimester AF cultures 
(Figure 1E). However, the adherent cells of 3
rd
-
trimester cultures appeared in a scattered manner 
with the detection of a few aggregates of no more 
than ten cells (Figure 1I). 
The primary AF cell cultures of 2
nd
 and 3
rd
 
trimesters had a heterogeneous morphology 
consisting of fibroblastoid-like morphology and small 
rounded resembling epithelial cells (Figure 1E) and 
(Figure 1I), respectively. During the subsequent 
passages, the cultures exhibited only typical 
fibroblastic cells. The epithelioid ones had no longer 
observed in cases of 2
nd
 trimester (Figure1F). While in 
some of 3
rd
 trimester AF cultures both morphologies, 
the fibroblastic and rounded epithelial, were shown 
(Figure 1J). Cultures at P3 in all AF samples had a 
homogenous typical fibroblast-like MSCs morphology 
(Figure 1H and Figure 1 L). 
The cells acquire senesce-like morphology 
(Figure 1L). The culture period in osteogenic media 
was 17 days from the third passage to osteogenic 
induction. The cell morphology showed elongated 
flattened cells with widened inter-cellular spaces 
(Figure 1L). 
 
Figure 1: Proliferation and culture expansion of BM-MSCs, 2
nd
 
trimester AF- MSCs & 3
rd
 trimester AF-MSCs; A-D) represented 
Bone marrow (BM) Proliferation & culture expansion at different 
passage; A) P0, B) P1, C) P2, D) P3 by x10 magnification; E-H) 
showed 2
nd
 trimester AF-MSCs Proliferation & culture expansion at 
different passage; E) P0; F) P1; G) P2; H) P3 by x 10 magnification; 
I-L) represented 3
rd
 trimester AF-MSCs Proliferation & culture 
expansion at different passage; I) P0; J) P1; K) P2; L) P3 by x 10 
magnification 
 
The BM-MSCs, 2
nd
 and 3
rd
-trimester AF-
MSCs after the first 14 days in osteogenic media are 
shown in Figure 2. There were three sets of plates, 
one set, in which cells continue in proliferation growth 
media (control), two sets in which, cells cultured in 
osteogenic media extended for two-time intervals, 14 
and 29 days. 
The BM-MSCs after 14 days in osteogenic 
medium were stained by Alizarin Red stain. The 
control plate showed a negative Alizarin stain (Figure 
2A), while the osteogenic plate showed weak to 
moderate staining intensity (Figure 2B). 
The 2
nd
-trimester AF-MSCs plates after 14 
days in osteogenic medium and staining by Alizarin 
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Red stain showed no calcium stained spots across the 
control plate (Figure 2C). The osteogenic plate 
showed multiple orange-red spots scattered all over 
the plate, including the periphery (Figure 2D). 
The 3
rd
-trimester AF-MSCs on day 14th of 
osteogenic induction: the control plate showed 
multiple stained patches of variable sizes (Figure 2E) 
and the osteogenic plate showed multiple stained 
spots and patches that were of more enhanced when 
compared to the control plate (Figure 2F).  
 
Figure 2: Osteogenic differentiation of BM-MSCs, 2
nd
 trimester AF-
MSCs and 3
rd
 trimester AF-MSCs after 14 days; Osteogenic 
differentiation of BM cells on day 14; A) Control; B) Osteogenic 
differentiation stained by Alizarin; Osteogenic differentiation of 2nd 
trimester AF cells; C) Control; D) Osteogenic differentiation stained 
by Alizarin after 14 days; Osteogenic differentiation of 3rd trimester 
AF cells; E) Control; F) Osteogenic differentiation stained by Alizarin 
after 14 days 
 
Cultured plates after the 28 days: BM-MSCs, 
2
nd
 & 3
rd
-trimester AF-MSCs in osteogenic media are 
shown in Figure 3. BM-MSCs cultures in the 
osteogenic medium stained with by Alizarin Red stain: 
The control plate, showed negative Alizarin stain 
(Figure 3A), while the osteogenic plate showed strong 
red staining intensity spots all over the plate (Figure 
3B). 
The 2
nd
-trimester AF-MSCs in osteogenic 
medium stained by Alizarin Red stain: The Control 
plate showed no stained spots across the plate 
(Figure 3C), while the osteogenic plate showed 
multiple orange-red stained spots (Figure 3D). 
The 3
rd
-trimester AF-MSCs in osteogenic 
medium stained by Alizarin Red stain: Control plate 
showed red-orange stained spots in few areas of the 
plate (Figure 3E), while the osteogenic plate showed 
strong red stained spots in multiple different parts 
across the plate (Figure 3F). 
 
Figure 3: Osteogenic differentiation of BM-MSCs, 2
nd
 AF-MSCs & 
3
rd
 AF-MSCs at 28 days; Osteogenic differentiation of BM cells on 
day 28
th
; A) Control; B) Osteogenic differentiation stained by 
Alizarin; Osteogenic differentiation of 2
nd
 trimester AF cells; C) 
Control; D) Osteogenic differentiation stained by Alizarin; 
Osteogenic differentiation of 3rd AF cells; E) Control; F) osteogenic 
differentiation stained by Alizarin 
 
In this study, we suggested that MSCs 
cultured in osteogenic differentiation medium may 
induce new bone formation in experimental spinal 
fusion rats. In pre- clinical experiments testing the 
therapeutic application of MSCs in bone regeneration, 
rat lumbar spines defects were surgically created and 
treated with undifferentiated and osteogenic 
differentiated MSCs, derived from BM and 2
nd
 
trimester AF. Cells were loaded on gel-foam scaffolds. 
X-ray radiography follows up, and histopathological 
analysis showed that AF-MSCs offer better healing 
effect and have a higher potential of achieving 
successful spinal fusion. 
The BM–rats group, after four months, the 
control rat, transplanted with undifferentiated MSCs 
showed no change at the lumbar spine, while one of 
the two osteogenic rats, who transplanted with 
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osteogenic differentiated MSCs, showed bone 
mottling, and a shadow area at the lumbar spine 
(Figure 4). 
The AF–rats group, after three months, the 
control rat (undifferentiated MSCs) showed no bone 
changes, whereas the two osteogenic rats 
(transplanted with osteoblastic 2
nd
 trimester AF- 
derived MSCs showed bone mottling (Figure 4). 
 
Figure 4: X-ray for AF-MSCs and BM-MSCs transplantation in rats. 
AF- and BM-derived undifferentiated MSCs, and differentiated 
osteogenic cells transplanted on decorticated lumber rat-spine 
beds. Among the BM group, after 4 months, the control rat, 
transplanted with undifferentiated MSCs showed no change at the 
lumbar spine. While, one of the two osteogenic rats transplanted 
with osteogenic differentiated MSCs, showed bone mottling, a 
shadow area at the lumbar spine. For the AF– group, after 3 
months, the control rat (undifferentiated MSCs) showed no bone 
changes. However, the two osteogenic rats (transplanted with 
osteoblastic 2
nd
 trimester AF- derived MSCs) showed bone mottling 
 
Histopathological examination of spinal-
decorticated rat lumber specimens that were 
transplanted with different grafts has been performed. 
Grafts used in this experiment were the osteogenic 
differentiated BM-MSCs versus undifferentiated BM-
MSCs as well as undifferentiated AF-MSCs versus 
osteogenic differentiated AF-MSCs (Figure 5). 
At four months post-transplantation, 
histopathological examination of sections of the rat 
transplanted with BM-MSCs differentiated into 
osteogenic progenitors showed the peripheral 
cartilage area that was followed by calcified cartilage 
and area of newly formed bone in contact with the 
host bone (Figure 5A). While the control rat received 
undifferentiated BM-MSCs exhibited irregular calcified 
areas that associated with few osteocytes and blood 
vessels (Figure 5B). 
At three months post-transplantation, 
microscopic examination of the defect section of the 
rat transplanted with matched AF-MSCs differentiated 
into osteogenic progenitor cells, showed calcified 
cartilage, newly formed bone, host bone and bone 
marrow (Figure 5C), while the control rat received 
matched undifferentiated AF-MSCs displayed calcified 
areas with few osteogenic foci at the top of the host 
bone (Figure 5D). 
 
Figure 5: Histopathological examination of sections of experimental 
and control rats, 4 months after transplantation with (BM-MSCs) & 3 
months after transplantation with (AF-MSCs) stained with 
hematoxylin and eosin dye. (A & B) Are sections of rat spinal defect 
transplanted with BM-MSCs, A) section of rat spinal defect 
transplanted with BM- MSCs differentiated into osteogenic 
progenitors shows cartilage area (short arrow), calcified cartilage 
(arrowhead) and formed new bone (long arrow) and host bone 
(asterisk). B) Section of rat spinal defect transplanted with 
undifferentiated BM-MSCs shows irregular calcified areas (short 
arrows) that associated with few osteocytes (arrowhead) and blood 
vessels (asterisk). (C & D) Represented sections of rat spinal injury 
transplanted with AF-MSCs, C) Section of rat spinal defect 
transplanted with AF-MSCs differentiated into osteogenic 
progenitors shows calcified cartilage (short arrow), newly formed 
bone (long arrow), host bone (arrowhead) and bone marrow 
(asterisk). D) Section of rat spinal defect transplanted with 
undifferentiated AF-MSCs shows calcified area with few osteogenic 
(short arrow) on the top of the host bone (arrowhead) (H&E, Scale 
bar: 20 µm) 
 
 
Discussion 
 
MSCs have a powerful ability to differentiate 
into a range of multi-cell types, including osteoblasts, 
adipocytes, chondrocytes, myoblasts, and neurons 
[27], [28]. The findings of Wang et al., (2018) reveal 
that the tumour antigen 15-leucine-rich repeat 
containing membrane protein (LRRC15) is an 
essential regulator for osteogenesis of MSCs through 
modulating p65 cytoplasmic/nuclear translocation [29]. 
The classic method of osteogenic 
differentiation of MSCs in vitro involves incubating a 
confluent monolayer of MSCs with ascorbic acid, 
beta-glycerophosphate, and dexamethasone for 2-3 
weeks. The MSCs form aggregates or nodules and 
increase their expression of alkaline phosphatase, 
and calcium accumulation can be seen over time. 
These bone nodules stain positively by alizarin red 
[30]. In our experiments, the standard osteogenic 
differentiation media and protocol worked very 
effectively and osteogenic differentiation indicated by 
alizarin nodules was obviously detected in cell 
cultures applying osteogenic differentiation media, 
whereas, no mineralized nodules were seen in 
comparable cultures with normal proliferation media 
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except in plates of 3
rd
 trimester AF, which might 
indicate the presence of shaded differentiated cells at 
that advanced gestational age. 
BM-MSCs generally serve as the „gold 
standard‟ against which other MSCs sources are 
compared. Previous studies demonstrated that 
populations of bone marrow-derived MSCs from 
human, canine, rabbit, rat, and mouse can develop 
into terminally differentiated mesenchymal 
phenotypes both in vitro and in vivo, including bone 
and cartilage [31], [32]. 
Amniotic fluid (AF) of second-trimester 
pregnancy has been used, many years ago, for 
prenatal diagnosis of genetic and chromosomal 
disorders. Research reports have shown that AF 
contains in addition to committed and differentiated 
cells a subpopulation with stem cell characteristics of 
multi-lineage differentiation, and expression of stem 
cell markers [33]. 
Amniotic fluid cells are heterogeneous, 
including cells shed from embryonic and extra- 
embryonic tissues. Ectodermal, mesodermal and 
endodermal cells can be found in amniotic fluid. 
Placental amnion may be derived from the epiblast as 
early as eight days after fertilisation. Thus, amnion 
epithelial cells are thought to retain the pluripotent 
properties of early epiblast cells, and these found in 
amniotic fluid and may serve as a source for 
mesenchymal stem cells [34]. The osteogenic 
commitment of AF-MSCs could be enhanced by using 
appropriate osteoconductive scaffolds and 
osteoinductive growth factors [35]. 
Amniotic fluid-derived stem cells (AF-MSCs) 
display high self-renewal capacity and plasticity, the 
second trimester derived cells, in particular, are 
rapidly expanded cells. Age of females and the stage 
of gestations constitute very important contributing 
factors marking AF properties. AF-MSCs showed the 
capacity to engraft and to contribute lineage-specific 
progeny in animal models. Therefore, AF-MSCs show 
great promise for use in cell-based therapeutic 
application in regenerative medicine. In this study, 
there was a significant difference in both the 
proliferation rate and osteogenic differentiation 
potentials of MSCs derived from the AF at different 
gestational ages a higher proliferation capacity and 
osteogenic potential compared to that of BM-derived 
cells. In a previous study, BM-MSCs showed a 
stronger osteogenic differentiation potential compared 
to adipose tissue-derived MSCs (AT-MSCs) [36]. 
Other investigators concluded similar findings 
are informing that the osteogenic differentiation 
potential of AF-MSCs is highly promising at both 2
nd
 
and 3
rd
 trimester when incubated in osteogenic media 
for 2 or 4 weeks [31]. The striking finding in our study 
was detecting osteoblastic progenitor cells in the 
cellular content of 3
rd
 trimester AF-MSCs, as clearly 
shown by detection of orange-red stained mineralised 
patches in control plates in which MSCs were 
continuously fed with MSCs proliferation media only. 
In general, cell attachment depends on the 
intrinsic characteristics of the cells and is modulated 
by choice of medium and supplements, the type of 
culture surface used as well as the interaction with 
heterotypic cell types. The combination of these 
factors influences the activation of the required signal 
transduction pathways leading to isolation and 
proliferation of the desired cell type [37]. 
In our in vivo study, transplantation of both 
osteogenic differentiated and undifferentiated MSCs, 
derived from bone marrow or AF (2
nd
 trimester) loaded 
on gel-foam and directly applied to the decorticated 
spines into rat-spines showed potential promising 
results. The x-rays, 3-4 months from the day of 
transplantation, showed a shadow (described as 
potential bone mottling) in one of the BM-groups, the 
rats transplanted with osteoblastic cells. In the AF-
MSCs group, the two rats transplanted with 
osteoblastic cells showed potential bone mottling on 
X-ray filming. Additional 3-4 months may be required 
to confirm that this mottling is a true bone-forming 
tissue. 
The use of AF-MSCs in cell therapy and 
tissue repair applications is yet in its beginning; 
however, several studies indicated that human 
amniocytes obtained by amniocentesis could be 
largely expanded and have the capacity to attach and 
proliferate on biodegradable scaffolds [38]. 
Osteogenically differentiated human CD117+ AFS 
(isolated by FACS separation) gave rise to tissue-
engineered bone grafts after subcutaneous 
transplantation into immune-deficient mice [19]. The 
therapeutic potential of human CD117+ AFS was also 
shown after subcutaneous implantation in athymic 
nude rats [38]. They produced mineralized structures 
and supported the functional repair of large bone 
defects. Unsorted human AFS, as in our case, were 
cultured under osteoblastic differentiation condition. 
They formed osteoblasts with detectable 
mineralization on titanium surfaces indicating a 
possible application in osteosynthesis. 
In this study, we suggested that MSCs 
cultured in osteogenic differentiation medium may 
induce the formation of new bone in experimental 
spinal fusion rats. X-ray radiography follows up, and 
histopathological analysis done three months post-
operation showed that AF-MSCs have a better healing 
effect and increasing the future likelihood of achieving 
successful spinal fusion. 
The present histopathological analysis was 
performed at three months post-cells transplantation 
of spinal-decorticated rat lumber specimens 
transplanted with AF-MSCs and at four months post-
cells transplanted with BM-MSCs grafts. Results 
observed represented some differences in bone 
formation between the AF-MSCs and BM-MSCs rat 
groups. The experimental rats transplanted with 
osteogenically differentiated BM-MSCs showed 
Basic Science 
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cartilage area, calcified cartilage (ossified) and newly 
formed bone, while the control rats that received 
matched undifferentiated BM-MSCs exhibited irregular 
calcified areas that associated with few osteocytes 
and blood vessels representing the beginning of bone 
repair healing phase. The experimental rats 
transplanted with osteogenically differentiated AF-
MSCs showed a more advanced stage than that of 
BM-MSCs rats involving calcified area with new bone 
structures contained osteocyte-like cells. The control 
rat received matched undifferentiated AF-MSCs 
showed calcified area with little osteogenic formed 
bone at the top of the host bone, which presents a 
more advanced stage of healing compared to that of 
BM-MSCs control rats. 
In conclusion, there was a significant 
difference noted between the 2
nd
-trimester AF-MSCs 
which have a greater proliferation capacity and typical 
fibroblast morphology compared to that of the 3
rd
-
trimester AF-MSCs which showed limited proliferation 
capacity in vitro. However, assessment of osteogenic 
differentiation of the AF-MSCs at early pregnancy 2
nd
 
trimester, versus late pregnancy 3
rd
 trimester, by 
Alizarin Red Staining has shown that the 3
rd
 trimester 
AF-MSCs contains osteoblast committed progenitor 
cells at both 14
th
 and 28
th
 days of osteogenic 
differentiation induction. However, both 2
nd
 and 3
rd
-
trimester AF-MSCs have greater proliferation capacity 
and osteogenic differentiation potentials in vitro 
compared to that of BM-MSCs. The in vitro osteogenic 
induction of MSCs derived from the two human 
sources; BM or 2
nd
 trimester AF before they're in vivo 
implantation, promotes their osteogenic/bone forming 
capacity and raising their healing effect. AF-MSCs, 
have a higher potential of inducing bone healing in 
vivo than that of BM-MSCs. Hence, they can be used 
as an alternative source to BM-MSCs in bone 
regeneration and spine fusion surgeries. Our findings 
suggested AF-MSCs a promising and safe alternative 
to BM-MSCs for cell therapy of bone defects and 
injury. 
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